In the savolitinib-osimertinib arm, the most common grade ≥3 adverse events included neutropenia (14%), leukopenia (7%), and increased alanine aminotransferase levels (7%), while in the group that received chemotherapy, neutropenia (26%) and anemia (23%) were the commonly observed grade ≥3 AEs. This evidence concerns the gene GPT and Decreased total neutrophil count.